All In MedTech

Device Trial Radar · NCT03230175

Phase 2 Pilot Trial of Subjects With Complex Non-healing Diabetic Foot Ulcers Treated With Standard Care Plus Cryopreserved Umbilical Cord Allograft (TTAX01)

A Multicenter, Open Label Phase 2 Pilot Trial of Subjects With Complex Non-healing Diabetic Foot Ulcers Treated With Standard Care Plus Cryopreserved Umbilical Cord Allograft (TTAX01)

Last checked: Nov 19, 2026Latest source record: Jun 15, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

32

Actual

Start

Oct 4, 2017

Primary completion

Jan 10, 2019

Study completion Apr 1, 2019

Sponsor

Lead sponsor
BioTissue Holdings, IncNot on our public-company list
Sponsor type
Industry
First posted
Jul 26, 2017

More device trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

It is hypothesized that application of the human placental umbilical cord tissue TTAX01 to the surface of a well debrided, complex diabetic foot ulcer will, with concomitant management of infection, result in a higher proportion of wounds showing complete healing within 16 weeks of initiating therapy.

Conditions

  • Non-healing Wound
  • Non-healing Diabetic Foot Ulcer
  • Diabetic Foot Infection

Interventions

  • TTAX01Biological

    TTAX01 will be applied directly to the wound surface and retained with non-absorbable sutures. A single layer of the test article should cover the entire open surface of the wound. The material is to be applied once every 4 weeks unless the wound shows evidence of healing, in which case dosing is suspended; or, if the test article has been accidentally dislodged, it may be replaced at any time.

  • Surgical resection and debridementProcedure

    Perform surgical sharp debridement in the OR, to remove: * infectious agents and biofilms (purulence), * all debris, eschar, callus and macerated non-viable tissue from the wound base, and * dead (suprabasal epidermis), scarred (elevated/edematous) and necrotic/macerated tissue from the wound edge. Surgical Resection will be performed to remove as much of the necrotic bone detected by the radiographic evidence as is appropriate.

  • Systemic antibioticsDrug

    Six (6) weeks of systemic antibiotic therapy is required. A definitive therapy will be guided by the microbiological results based on bone biopsy.

  • Off-loadingDevice

    Provide off-loading device appropriate to the location of wound with full length boot or total contact cast

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Subjects With Complete Wound HealingTime frame: 16-weeks

Locations

11 sites in 1 country. Site status is shown where the registry gives one.

  • Banner University Medical Center

    Phoenix, Arizona

  • UCLA Olive View

    Sylmar, California

  • University of Miami

    Miami, Florida

8 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.